US FDA Seeks Ways To Prevent Non-Responders From Sinking Tissue-Agnostic Indications
Agency officials and oncologists debate considerations where a data package overwhelms non-responders in favor of a tissue-agnostic indication.
You may also be interested in...
New oncologics bring CDER’s novel agent approvals count to 53 for the year.
But reminds sponsors that more trials could be ordered post-approval, which may be important in face of evidence that tissue-agnostic cancer therapies are not always equally effective.
Accelerated approval for patients with microsatellite instability-high or mismatch repair deficient solid tumors is the first time the US FDA has granted an indication that does not specify the location of the tumor – a change precision medicine researchers have been eager to make.